Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:28
01/28/20
01/28
12:28
01/28/20
12:28
PFE

Pfizer

$38.40 /

-1.76 (-4.38%)

, MMM

3M

$165.66 /

-10.04 (-5.71%)

, UTX

United Technologies

$153.65 /

+2.53 (+1.67%)

, DLPH

Delphi Technologies

$15.57 /

+5.78 (+59.04%)

, BWA

BorgWarner

$35.09 /

-3.29 (-8.57%)

, XLRN

Acceleron

$75.05 /

+22.22 (+42.06%)

, LAUR

Laureate Education

$20.32 /

+2.62 (+14.80%)

, LOPE

Grand Canyon

$85.37 /

-6.075 (-6.64%)

, MKC

McCormick

$167.20 /

-5.54 (-3.21%)

Stocks are rebounding a…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
J&J says at work on potential preventive coronavirus vaccine » 11:34
01/28/20
01/28
11:34
01/28/20
11:34
JNJ

Johnson & Johnson

$149.99 /

+1.34 (+0.90%)

In a post to its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Horizon Therapeutics to purchase three-building campus in Deerfield » 11:14
01/28/20
01/28
11:14
01/28/20
11:14
HZNP

Horizon Therapeutics

$36.01 /

-0.03 (-0.08%)

, TAK

Takeda Pharmaceutical

$19.76 /

+0.025 (+0.13%)

Horizon Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Nektar call volume above normal and directionally bullish » 10:45
01/28/20
01/28
10:45
01/28/20
10:45
NKTR

Nektar

$20.64 /

+0.88 (+4.45%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Hard to know how positive Incyte's TRuE-AD2 without data, says Piper Sandler » 10:38
01/28/20
01/28
10:38
01/28/20
10:38
INCY

Incyte

$77.25 /

+1.15 (+1.51%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Incyte results in eczema positive, though largely anticipated, says Mizuho » 10:19
01/28/20
01/28
10:19
01/28/20
10:19
INCY

Incyte

$76.63 /

+0.53 (+0.70%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein noted that Incyte announced positive topline results from its TRuE-AD2 study evaluating ruxolitinib cream in patients with atopic dermatitis, or eczema. While the efficacy and safety data was consistent to what was observed in the Phase 2 trial, this was largely anticipated, according to Goldstein. She sees ruxolitinib cream as a positive, but believes the bigger questions for Incyte relate to commercialization in atopic dermatitis and the data for the TRuE-V program in vitiligo, which she sees as the larger opportunity. She keeps a Neutral rating on Incyte shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusually active option classes on open January 28th » 09:40
01/28/20
01/28
09:40
01/28/20
09:40
FNV

Franco-Nevada

$110.02 /

+ (+0.00%)

, BKR

Baker Hughes

$22.06 /

+ (+0.00%)

, MMM

3M

$175.70 /

+ (+0.00%)

, PFE

Pfizer

$40.16 /

+ (+0.00%)

, EEM

iShares MSCI Emerging Markets ETF

$43.07 /

+ (+0.00%)

, ABBV

AbbVie

$84.03 /

+ (+0.00%)

, CGC

Canopy Growth

$21.54 /

+ (+0.00%)

, LVS

Las Vegas Sands

$63.26 /

+ (+0.00%)

, WMT

Walmart

$115.89 /

+ (+0.00%)

, UBER

Uber

$36.30 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Franco-Nevada (FNV), Baker Hughes (BKR), 3M (MMM), Pfizer (PFE), iShares Emerging Markets ETF (EEM), AbbVie (ABBV), Canopy Growth (CGC), Las Vegas Sands (LVS), Wal-Mart (WMT), and Uber (UBER).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: Pre-market Movers » 09:04
01/28/20
01/28
09:04
01/28/20
09:04
DLPH

Delphi Technologies

$9.79 /

-0.04 (-0.41%)

, BWA

BorgWarner

$38.38 /

-0.87 (-2.22%)

, XLRN

Acceleron

$52.83 /

+0.81 (+1.56%)

, LMT

Lockheed Martin

$432.31 /

-0.31 (-0.07%)

, PHM

PulteGroup

$44.34 /

+0.62 (+1.42%)

, ALV

Autoliv

$74.24 /

-3.075 (-3.98%)

, PFE

Pfizer

$40.16 /

+0.34 (+0.85%)

, UTX

United Technologies

$151.12 /

-2.05 (-1.34%)

, MMM

3M

$175.70 /

-2.48 (-1.39%)

, MKC

McCormick

$172.74 /

+0.005 (+0.00%)

, HOG

Harley-Davidson

$34.86 /

-0.37 (-1.05%)

, BYND

Beyond Meat

$124.64 /

+5.15 (+4.31%)

HIGHER: Delphi…

HIGHER: Delphi Technologies (DLPH), up 62% after announcing a deal under which BorgWarner (BWA) will acquire the company in an all-stock transaction that values Delphi's enterprise value at approximately $3.3B. BorgWarner shares are down 7% in pre-market trading following the announcement... Acceleron (XLRN), up 50% after announcing its sotatercept trial met its primary and secondary endpoints. UP AFTER EARNINGS: Lockheed Martin (LMT), up 1%... PulteGroup (PHM), up 2%... Autoliv (ALV), up 4%. DOWN AFTER EARNINGS: Pfizer (PFE), down 2%... United Technologies (UTX), down 1%... 3M (MMM), down 2%... McCormick (MKC), down 6%.... Harley-Davidson (HOG), down 6%. ALSO LOWER: Beyond Meat (BYND), down 1% after a judge has ruled Don Lee Farms proved the probable validity of its claim that the company breached a manufacturing agreement. In a separate motion before a different Judge, the court granted Don Lee Farms' request to name Beyond Meat CFO Mark Nelson, senior quality assurance manager Jessica Quetsch and director of operations Anthony Miller in its fraud claims which allege they intentionally doctored and omitted material information from a food safety consultant's report. Additionally, JPMorgan analyst Ken Goldman downgraded Beyond Meat to Neutral from Overweight with a price target of $134, down from $138.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Acceleron after-market rally on data 'somewhat excessive,' says JPMorgan » 08:57
01/28/20
01/28
08:57
01/28/20
08:57
XLRN

Acceleron

$52.83 /

+0.81 (+1.56%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph views the after-market rally of 65% in shares of Acceleron Pharma as "somewhat excessive" if sustained. While the pulmonary arterial hypertension top-line data is a "clear win," the strong reaction is potentially reflective of rising takeover expectations, Joseph tells investors in a research note. The analyst awaits fuller Phase 2 data to better inform sotatercept's probability of success and commercial penetration assumptions. He keeps an Overweight rating on Acceleron, whose stock is up 51% to $79.62 in premarket trading.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Syros Pharmaceuticals doses first patient in SY-5609 Phase 1 clinical trial » 08:36
01/28/20
01/28
08:36
01/28/20
08:36
SYRS

Syros Pharmaceuticals

$7.26 /

+0.03 (+0.41%)

Syros Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.